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Abstract
Anti-glycan antibodies directed against gangliosides are now considered the major immune effectors
that induce damage to intact nerve fibers in some variants of the monophasic neuropathic disorders
that comprise Guillain-Barré syndrome. Recent experimental studies elucidating the complexity of
anti-glycan antibody-mediated pathobiologic effects on intact and injured nerves undergoing repair
are discussed.
Introduction and context
Guillain-Barré syndrome (GBS) is a group of acute,
monophasic, and pathophysiologically heterogenous
neuropathic disorders. Paralytic forms of the disorder
are classified (Table 1) as demyelinating or axonal based
onelectrophysiology,whereasrelativelyrarenon-paralytic
variants include Fisher syndrome (FS), characterized by
ophthalomplegia, ataxia, and areflexia [1,2]. With the
near eradication of polio, paralytic variants of GBS are the
commonest cause of acute flaccid paralysis worldwide.
GBS is considered to be an autoimmune disease triggered
frequently by common infections of upper respiratory
and gastrointestinal tracts [1-3] in a susceptible host [4].
What constitutes a susceptible host remains enigmatic.
Autoantibodies directed against cell surface glycans
carried by gangliosides (sialic acid-containing glyco-
sphingolipids enriched in peripheral nerve fibers) have
become the main focus of research in GBS. Over the last
15-20 years, several lines of evidence have linked these
autoantibodies to the pathogenesis of GBS, particularly
to axonal and Fisher variants of the disease. The clinical
studies focusing on serological immune markers and
GBS phenotype and recovery have identified associations
of specific anti-glycan antibodies with different variants
of GBS [3] and poor recovery [5,6]. The association
studies have implied that specific anti-glycan antibodies
not only can induce neuropathy (i.e., injury to intact
nerve fibers) but also can adversely affect recovery by
inducing more severe neuropathic disease or interfering
with the nerve repair process required for recovery (or
both). Identification of specific anti-glycan antibodies in
GBS patients led to the development of cell culture [7],
tissue culture [8-10], and animal [11-14] models that
showed the pathogenetic effects of anti-glycan anti-
bodies on intact nerves or nerve cells. Cumulatively,
these studies indicate that specific anti-glycan antibodies
target relevant antigens in neural cells, especially at
motor nerve terminals or nodes of Ranvier (or both) to
disrupt the nerve fiber function [15-17]. Human and
experimental studies indicate that complement activa-
tion is involved in structural injury to the nerve fibers
[18-20]. Several issues regarding the anti-glycan anti-
body-mediated nerve injury remain unresolved [21]. For
example, unconditional passive transfer with sera con-
taining anti-glycan antibodies obtained from patients or
active immunization animal models of axonal GBS
[11,13] has not been reported to induce injury to the
intact nerve fibers in experimental animals. This brief
review describes some salient recent developments that
enhance our understanding of the complex pathobiolo-
gic mechanisms involved in anti-glycan antibody-
mediated deleterious effects on intact and injured nerve
fibers.
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Several recent observations are beginning to unravel the
complexity involved in anti-glycan antibody-associated
selective nerve fiber injury seen in different variants of
GBS. For example, antibodies against GM1 and GD1a or
related minor gangliosides are associated with acute
motor axonal neuropathy (AMAN) and anti-GQ1b/
GT1a with FS [1-3]. The association of specific anti-glycan
antibodies with specific GBS variants had raised an
important critique; that is, how do specific anti-glycan
antibodies induce selective injury to different nerve fibers
(e.g., motor versus sensory) or selective topographical
involvement of nerves/pathways despite minor or no
differences in the biochemical content of gangliosides in
different nerves or nerve fibers? The group led by
Kusunoki [22], in a series of studies, have presented a
novel concept that some GBS sera/anti-glycan antibodies
bind to ganglioside complexes (pairs of gangliosides) but
not to individual components of ganglioside in solid-
phase assays. The authors propose that antibodies against
ganglioside complexes recognize new conformational
epitope(s)formedbymixing.Whetherornotgangliosides
and other glycans that constitute cell surface glycocalyx
form complexes or unique conformational epitopes in
biological/cellular membranes remains to be determined.
If this concept is validated, then this has far-reaching
implications and could provide an explanation of how
different neuronal/nerve fiber populations could be
selectively targeted by specific anti-glycan antibodies
despite similar biochemical content of individual major
gangliosides. That an individual ganglioside can assume a
different conformation/orientation in motor and sensory
fibers was supported by data published by our group
recently [23]. This study focused on anti-GD1a antibodies
in the context of AMAN and selective motor fiber injury.
We found that some anti-GD1a antibodies selectively
bound to motor but not sensory axons and that different
anti-GD1a antibodies had different binding patterns to
various chemical derivatives of GD1a (fine specificity).
On the basis of data derived from biochemical, immu-
nocytochemistry, computer modeling, and enzymatic
studies, we proposed a model in which critical GD1a
epitopes recognized by selective motor anti-GD1a anti-
bodies are differentially expressed in motor and sensory
nerves. Yet another mechanism was suggested by a study
showing that motor nerve terminal injury with anti-GM1
antibodies was enhanced with prior enzymatic treatment
with sialidase [24]. Based on these findings, it was
proposed that a proportion of GM1 ganglioside is cryptic
due to masking by other moieties in the cell membrane,
including more complex gangliosides. Overall, this set of
studies suggests that selective topographical injury of
nerves/nerve fibersin GBS is a complex issue and multiple
complementary mechanisms are likely to contribute.
Translational progress has also been made in the area of
anti-glycan antibody-mediated complement-dependent
nerve fiber injury. The Willison group in Glasgow
published a series of studies showing that specific anti-
glycan antibodies bind to motor nerve terminals or
perisynaptic Schwann cells (or both) and activate
complement and this not only disrupts neuromuscular
transmission but also can induce degeneration of motor
nerve terminals (reviewed in [25]). Susuki et al. [17]
extended this line of research and examined the role of
complement at the nodes of Ranvier in a rabbit model of
AMAN. They showed that during the acute phase of limb
weakness, deposition of IgG and complement correlates
with disruption of voltage-gated sodium channel clusters
and paranodal axoglial junctions, the nodal cytoskeleton
(Figure 1), and Schwann cell microvilli, all of which
stabilize these channels at the nodes. These pathogenic
studies led to translational efforts focusing on comple-
ment inhibition. Halstead et al., in two separate studies
[14,26],showthattwoinhibitorsofC5(i.e.,C5-inhibiting
recombinant protein rEV576 and eculizumab [Soliris®;
Alexion Pharmaceuticals, Cheshire, CT, USA], a treatment
approved by the US Food and Drug Administration for
paroxysmal nocturnal hemoglobinuria) prevented phy-
siological and structural damage to motor nerve fibers
in preclinical models. Based on these observations, an
argument has been put forth for a clinical trial with
eculizumab in GBS.
In a multi-investigator collaborative study, Buchwald et al.
[27] show that anti-glycan (GM1 and GD1a) antibodies
can induce various degrees of synaptic blockade (evoked
quantal release) at neuromuscular junctions indepen-
dently of complement. The same antibodies significantly
reduced depolarization-induced calcium influx in neu-
rons. This study was conducted with the following clinical
observations in view: (a) some patients with axonal GBS
recovertoorapidlytoexplaintheirrecoveryonthebasisof
axon degeneration and regeneration, and (b) some
subjects (patients or animals with axonal GBS) with
Table 1. Classification of Guillain-Barré syndrome
Paralytic forms
- Demyelinating electrophysiology
- Acute inflammatory demyelinating polyradiculoneuropathy (AIDP)
Axonal electrophysiology
- Acute motor axonal neuropathy
- Acute motor-sensory axonal neuropathy
- AIDP with secondary axonal degeneration
Regional or focal paralytic forms
- Fisher syndrome
- Oropharyngeal
Non-paralytic forms
- Sensory ataxic variant
- Acute pandysautonomia
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significant pathology that would explain their weakness
[28,29]. These experimental studies support the notion
that anti-glycan antibody-induced deleterious effects on
presynaptic transmitter release is one pathophysiological
mechanism of antibody-mediated muscle weakness in
AMAN.
Our group examined, for the first time, the effects of anti-
glycan antibodies on peripheral nerve repair/axon
regeneration in an animal model [30]. We found that
passive transfer of anti-GD1a reactive antibodies severely
inhibited axon regeneration after peripheral nervous
system injury. In mutant mice with altered ganglioside or
complement expression, inhibition by antibodies was
mediated directly via GD1a and was independent of
complement-induced cytolytic injury. The impaired
regenerative responses and ultrastructure of injured
peripheral axons mimicked dystrophic and stalled
growth cones (Figure 2B,C) typically seen after central
nervous system injury. We have also seen dystrophic/
stalled growth cones in the sural nerve biopsy of a GBS
patient who had poor recovery (Figure 2A). These
observations support the hypothesis that inhibition of
axon regeneration is one mechanism of poor recovery in
GBS patients with anti-glycan antibodies. Furthermore,
these studies indicate that circulating factors such as
autoimmune autoantibodies can inhibit axon regenera-
tion and affect recovery in patients with GBS.
Future directions
The notion that anti-glycan antibodies are the primary
pathogenetic effectors in GBS continues to be contested.
The controversy stems mainly from the fact that
experimental modeling in different studies has yielded
varied results [31,32]. It is not surprising that experi-
mental modeling is not reproducible given that tradi-
tionally only enzyme-linked immunosorbent assay has
been used to define the specificity of anti-glycan
antibodies for further use in experimental studies. Recent
work, some of which is outlined above, indicates that
anti-glycan antibody-mediated pathogenecity is quite
complex, partly due to subtleties involved in the
carbohydrate antigen expression on the neural cell
surfaces. Furthermore, anti-glycan antibodies with spe-
cificity for a ganglioside are not created equally and these
antibodies could be different in terms of fine specificity,
tissue-binding patterns, affinity/avidity, Fc-based effector
functions, and other as-yet-undefined properties. The
development of techniques that allow the examination
of different characteristics of glycan antigens and anti-
glycan antibodies and increasing use of well-defined
monoclonal anti-glycan antibodies is very likely to
decrease discrepant experimental findings. The charac-
terization of different properties of anti-glycan antibo-
dies is likely to extend into the clinical arena for
delineation of well-defined subgroups of GBS patients
(or other immune neuropathies associated with anti-
glycan antibodies) for clinical outcome research and
enrolment in clinical trials as new therapies emerge.
The elucidation of mechanisms underlying anti-glycan
antibody-mediated injury to intact nerve fibers has been
a fruitful line of research. A direct result of this is the
emergence of complement inhibitors as candidates for
clinical trials in GBS and other immune neuropathies
[14]. It is anticipated that detailed intracellular signaling
mechanisms/pathways mediating anti-glycan antibody-
induced injury to intact nerve fibers will be identified.
The identification of these pathways may allow the
Figure 1. Disruption of voltage-gated sodium (Nav) channels and
related cytoskeletal molecules at nodes of Ranvier in a rabbit
model of acute motor axonal neuropathy (AMAN)
All panels show longitudinal sections of ventral roots, and nerve fibers run
horizontally. Sections were immunostained with antibodies to C3 (green),
Nav channels (blue), and bIV spectrin (red). (A) A normal node of Ranvier in
a control rabbit, showing absence of complement deposition and normal
distribution of the Nav channel and bIV spectrin. (B) A node of Ranvier in
an AMAN rabbit at the acute progressive phase, showing that deposition
of complement was associated with disruption of nodal architecture
(paranodal axoglial junctions/lengthening) and Nav channel and bIV spectrin
staining. Adapted with permission from Figure 4, Susuki et al. [17].
© Copyright 2007, Society for Neuroscience.
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use in conjunction with current immunomodulatory
treatments to minimize nerve damage during the injury
(acute) phase of GBS and other immune neuropathies.
Models of anti-glycan antibody-mediated inhibition of
nerve repair have already been established and it is very
likely that these models will allow the dissection of
molecular mechanisms that prevent successful nerve
repair and recovery. Novel therapeutic strategies targeting
the signaling pathways that prevent successful regenera-
tion may allow enhanced nerve repair not only in patients
with GBS but in those with other neuropathic conditions.
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